ASX Announcements
Memphasys is committed to providing shareholders with complete, up-to-the-minute information about the Company. Contact, stock, and corporate information can be found in this section of the website and on the Australian Securities Exchange.
27 October 2022 – September Quarterly Activities / 4C
25 October 2022 – Notice of AGM / Proxy Form
24 October 2022 – FELIX commercialisation & trial plan
21 September 2022 – Appendix 2A
19 September 2022 – Rights Issue Closure & Shortfall
5 September 2022 – Non-Renounceable Issue
5 September 2022 – Appendix 3B
31 August 2022 – Full Year Statutory Accounts
31 August 2022 – Preliminary Final Report
31 August 2022 – Appendix 4G & Corp Gov Statement
29 August 2022 – Rights Issue Prospectus despatched
25 August 2022 – Application for quotation of securities
18 August 2022 – Non-Renounceable Issue – Website Disclaimer
18 August 2022 – Update – Proposed issue of securities
17 August 2022 – Proposed issue of securities
17 August 2022 – Reinstatement to Official Quotation
17 August 2022 – $3.36m capital raising
11 August 2022 – Court Orders Granted
2 August 2022 – Cleansing Statement
29 July 2022 – Quarterly Activities / 4C
29 July 2022 – Suspension from Official Quotation
27 July 2022 – Trading Halt
28 June 2022 – Monash IVF study enrols first patient
27 June 2022 – Notification of cessation of securities
9 June 2022 – Felix System commercialisation update
6 June 2022 – Notification of cessation of securities
17 May 2022 – Response to ASX Query
26 April 2022 – Final Director’s Interest Notice SH
26 April 2022 – Initial Director’s Interest Notice – RC
26 April 2022 – Non-Exec Chair Appointment & Resignation
12 April 2022 – Quarterly Activities / 4C
3 March 2022 – Creating Novel Fertility Solutions
25 January 2022 – Quarterly Activities / 4C
24 January 2022 – Change of Directors Interest Notice
19 January 2022 – Sale of Convertible Note to Peters Investments